MIM
SNDX icon

MetLife Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History

MetLife Investment Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Buy
51,930
+5,092
+11% +$106K 0.01% 1465
2026
Q1 		$1.09M Sell
46,838
-2,894
-6% -$62.9K 0.01% 1353
2025
Q4 		$1.04M Hold
49,732
– – 0.01% 1402
2025
Q3 		$765K Hold
49,732
– – ﹤0.01% 1602
2025
Q2 		$466K Hold
49,732
– – ﹤0.01% 1708
2025
Q1 		$611K Sell
49,732
-783
-2% -$11K ﹤0.01% 1614
2024
Q4 		$668K Buy
50,515
+2,961
+6% +$50.7K ﹤0.01% 1635
2024
Q3 		$915K Hold
47,554
– – 0.01% 1442
2024
Q2 		$976K Buy
47,554
+7,230
+18% +$151K 0.01% 1360
2024
Q1 		$960K Buy
40,324
+5,569
+16% +$124K 0.01% 1324
2023
Q4 		$751K Hold
34,755
– – 0.01% 1455
2023
Q3 		$505K Hold
34,755
– – ﹤0.01% 1630
2023
Q2 		$727K Buy
34,755
+3,126
+10% +$65.1K 0.01% 1449
2023
Q1 		$668K Buy
31,629
+3,702
+13% +$92.1K ﹤0.01% 1463
2022
Q4 		$711K Buy
27,927
+898
+3% +$20.9K 0.01% 1409
2022
Q3 		$650K Hold
27,029
– – 0.01% 1448
2022
Q2 		$520K Hold
27,029
– – ﹤0.01% 1634
2022
Q1 		$470K Buy
27,029
+9,976
+58% +$168K ﹤0.01% 1808
2021
Q4 		$373K Hold
17,053
– – ﹤0.01% 1659
2021
Q3 		$326K Hold
17,053
– – ﹤0.01% 1776
2021
Q2 		$293K Buy
17,053
+5,838
+52% +$107K ﹤0.01% 1906
2021
Q1 		$251K Hold
11,215
– – ﹤0.01% 1929
2020
Q4 		$249K Hold
11,215
– – ﹤0.01% 1855
2020
Q3 		$166K Hold
11,215
– – ﹤0.01% 1976
2020
Q2 		$166K Hold
11,215
– – ﹤0.01% 2005
2020
Q1 		$123K Buy
+11,215
New +$105K ﹤0.01% 1966

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

MetLife Investment Management's SNDX Position: Q2 2026 in Review

MetLife Investment Management increased its Syndax Pharmaceuticals (SNDX) stake by 11% in Q2 2026, buying an estimated $106K and bringing the position to 51,930 shares worth $1.14M. The position accounts for 0.01% of the portfolio, ranked #1465.

MetLife Investment Management first reported a position in SNDX in Q1 2020 and has held it in 26 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • MetLife Investment Management held 51,930 shares of Syndax Pharmaceuticals worth $1.14M as of Q2 2026.
  • MetLife Investment Management bought 5,092 Syndax Pharmaceuticals shares in Q2 2026, an estimated $106K.
  • Syndax Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1465 holding.
  • MetLife Investment Management first reported a position in Syndax Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.